cells

Discovery Pipeline

DISCOVERY PIPELINE

Immuno-Oncology Target

icon

CD39

Exo-nucleotidase

CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1

Additional undisclosed targets.

Cancer Cell Intrinsic Target

icon

HIF-2𝛂 Inhibitor

Transcription factor

HIF-2Ξ± is a master transcriptional regulator of multiple genes involved in tumor progression.2

icon

AXL Inhibitor

Tyrosine kinase

AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.3

Additional undisclosed targets.

HIF-2𝛂, hypoxia-inducible factor 2-alpha

References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739–755 (2020). 2. Murugesan T, Rajajeyabalachandran G, Kumar S, Nagaraju S, Kumar S. Targeting HIF-2Ξ± as therapy for advanced cancers. Drug Discov Today. 2018;23(7):1444-1451. 3. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.